Introduction
Bypassing agents have been the primary therapeutic option for hemophilia patients with high responding inhibitors (titers ≥ 5.0 Bethesda Units) for many years. Although greatly superior to earlier therapies such as plasmapheresis, bypassing agents have been associated with inconsistent predictability since the earliest uses of prothrombin complex concentrates (PCC), activated PCC (APCC) and recombinant factor VIIa (rFVIIa) [1, 2] . Although often attributed to the bypassing agent itself, this lack of predictability may arise from a combination of patient-and treatment-specific influences, including the heterogeneity of bleeding events, time to treatment, individual patient response, lack of familiarity in their use, and under-dosing for fear of thrombotic side-effects. Although therapies for hemophilia have expanded in recent years, treatment options for inhibitor patients were virtually stable for almost two decades. During this period clinicians achieved greatly improved clinical outcomes through empirical observation, reviews of registry data, and investigations into the biological mechanism of action of bypassing agents.
Gene therapy has shown rapid advances in non-inhibitor hemophilia patients; as yet, patients with inhibitors are not eligible for these protocols. For inhibitor patients, mechanism of action-based research has led to new prospective clinical studies with promising outcomes, with the recent approval of the first non-factor-based therapy, emicizumab-kxwh (Hemlibra Ò , Roche, Basel, Switzerland) being a clear example. As we enter an era of improved therapeutics for inhibitor patients, the use of traditional bypassing agents may be expected to decrease; yet they will remain a necessity for the treatment of breakthrough bleeds in hemophilia A with inhibitors, and as the mainstay of treatment in patients with hemophilia B with inhibitors until novel agents applicable to this population also become available [3] . This review focuses on our understanding of the mechanism of action and the optimal use of traditional bypassing agents. The pipeline of potentially transformative products currently being developed will be reviewed along with a discussion of how these agents and traditional bypassing agents might theoretically be administered together.
Traditional bypassing agents
Twenty years ago, it was common for inhibitor-related bleeding events to be prolonged. Today, clinicians are able to individualize and optimize bypassing agent therapies to achieve rapid bleed control in most circumstances, despite the lack of clinically validated assays to determine hemostatic status (recently, techniques such as thromboelastography, which measure changes in the viscoelasticity of blood during clot formation, have shown potential for clinical use [4, 5] ).
Currently, bleeding is viewed as a time-sensitive and volume-dependent pathologic continuum. This time period can be viewed as comprised of three intervals: time from bleed onset to recognition, time from recognition to initiation of treatment, and time from initiation of treatment to clinical response. The first interval is dependent on patient education and a variety of other issues, including arthritis or associated injury. The second is dependent on patient education, sense of urgency and access to therapy. The third may be dependent on the severity of the bleed or associated injury, product and dose utilized, and individual response. The treatment goals of early recognition, prompt initiation of therapy and rapid bleed control are essential to limit immediate and long-term sequelae.
The healthcare cost of inhibitor patients is high and may limit access to therapy. An analysis by Earnshaw et al. in 2014 estimated the lifetime drug and hospitalization cost at over $43 million/patient for a prophylactic bypassing agent regimen in the USA ($613 000 per year), a figure that reflects high drug cost, the number of bleeding episodes and the anticipated hospitalizations and surgeries. On-demand treatment was estimated to incur over $21 million in lifetime costs, albeit with a reduced quality of life compared with prophylaxis [6] .
On-demand dosing with APCC APCC (FEIBA Ò , anti-inhibitor coagulant complex, Shire, Dublin, Ireland) is a plasma-derived bypassing agent comprising multiple zymogens and activated coagulation factors. Its efficacy is primarily driven by prothrombin and activated factor X (FXa), with other components such as FVIIa playing a complementary role in its hemostatic effect [7] . Zymogen accumulation may occur with repeated use; for example, prothrombin has a half-life of 72 h. Because of the potential risk of thrombotic complications, a maximum daily dose of 200 U kg À1 is recommended, with individual doses ranging from 50 to 100 U kg À1 every 6 or 12 h, depending on the type of bleed. The volume and duration of APCC infusion have an impact on use: the US DOSE study indicated the mean preparation and administration times were 23.2 and 30.8 min, respectively, the latter matching the manufacturer's recommendations [8] . Interestingly, the predominantly European-based FEIBA Ò PASS observational study reported mean infusion rates to be twice that recommended by regulatory agencies, with the highest infusion rate being 12 times the maximum recommended rate of 2 U kg À1 min À1 [9] . These accelerated infusion rates
were not reported to be associated with systemic manifestations or other adverse events such as thrombotic complications; however, systemic reactions have previously been reported with increased infusion rates [10] . A prospective clinical study to examine reduced infusion volumes and accelerated infusion times with FEIBA Ò is anticipated to begin in 2018 [11] .
On-demand dosing with rFVIIa (NovoSeven â , eptacog alfa)
Recombinant FVIIa (NovoSeven Ò , eptacog alfa, Novo Nordisk, Bagsvaerd, Denmark) activates the extrinsic coagulation pathway, bypassing the need for factor VIII (FVIII) or factor IX (FIX); a typical dose can boost FVIIa plasma levels > 100-fold above normal. rFVIIa was initially licensed for use at 90 lg kg À1 administered every 2 h until hemostasis was achieved; however, doses of~270 lg kg À1 have been utilized in clinical practice, with reports of increased response rates and convenience as a result of longer intervals between infusions. Administration of higher doses of rFVIIa may result in an increased thrombin burst and improved bleed control [12] . Observational studies lacking statistical significance have supported this concept [13, 14] ; however, prospective clinical studies with eptacog alfa (NovoSeven Ò ) have not demonstrated increased efficacy with a high dose compared to a regimen of multiple smaller doses [12, 15, 16] . Instead, one 270 lg kg À1 dose has been shown to be roughly comparable to three sequential 90 lg kg À1 doses administered at 3-h intervals. These higher doses have repeatedly been shown to be safe, and the risk of thrombosis in inhibitor patients lacking thrombotic risk factors is low [17] ; experience in elderly patients is limited. Despite the lack of statistically significant data showing improved efficacy with higher doses, rFVIIa is indicated for use at both 90 and 270 lg kg À1 in the EU (European Union), with the higher dose being recommended in certain circumstances [18] ; in the USA and Canada, licensure is limited to 90 lg kg À1 dosed every 2 h.
Compared with APCC, rFVIIa has shorter mean preparation and administration times (6.5 and 5.7 min, respectively) [8] . A Bayesian meta-regression model using data from over 2000 published bleeding events predicted greater efficacy for rFVIIa (66% at 12 h, 88% at 24 h and 95% at 36 h) compared with APCC (39% at 12 h, 62% at 24 h and 76% at 36 h) [19] ; however, a controlled head-to-head comparison in the FENOC study showed similar overall efficacy between the two products, although the regimens studied are not necessarily reflective of the current standard of care [20] .
On-demand dosing with rFVIIa (eptacog beta)
During the development of the rFVIIa variant eptacog beta (LFB, Les Ulis, France/HEMA Biologics, Louisville, KY, USA), the long-theorized clinical dose-dependence was observed: a statistically significant improvement in efficacy was noted when the product was administered at a higher initial dose compared with the same cumulative dose administered as multiple smaller infusions [3, 21] . It was also shown that the majority of bleeding events (85%) could be successfully treated with a single 225-lg kg À1 dose, whereas lower doses (75 lg kg
À1
) required multiple treatments and a longer treatment time to achieve the same rate of hemostatic success [3] . These observations align with the current treatment goal of rapid hemostasis.
On-demand sequential dosing with APCC/rFVIIa
Patients may have an improved response to one bypassing agent compared with the other, and this response may change over time, including during the course of a single hemorrhage [20, 22] . In addition, 10-20% of bleeding events may not be effectively controlled with either APCC or rFVIIa [23] . In hospitalized patients, some unresponsive severe bleeds have been successfully treated with sequential dosing of both APCC and rFVIIa. Gringeri et al. reported 11 cases of unresponsive hemorrhage, which when treated with a sequential APCC/rFVIIa regimen, resulted in bleed control within 12-24 h in all cases [23] . No clinical signs of thrombosis were noted, although D-dimer levels were elevated in several subjects. Other clinicians have noted similar results [24, 25] ; however, severe complications such as pulmonary embolism have been reported, highlighting the need for caution if both products are administered [26] . Sequential APCC/rFVIIa therapy requires close clinical monitoring by knowledgeable care providers because of the increased risk of thrombotic events; it is not considered an outpatient therapy.
Prophylaxis with APCC or rFVIIa
Both APCC and rFVIIa are utilized in prophylactic regimens to suppress development of bleeding events. A variety of dosing regimens have been reported: rFVIIa is most commonly administered daily; dosing with APCC varies but is typically administered three to five times a week, depending on the patient. Studies examining rFVIIa (PRO-PACT) and APCC (PRO-FEIBA) support the prophylactic use of these agents, with subjects experiencing fewer bleeding events and an increase in healthrelated quality of life [27] [28] [29] [30] [31] .
The role of APCC prophylaxis in slowing or preventing joint damage is patient and joint dependent: one study suggested that APCC prophylaxis might prevent joint damage or slow its progression, whereas others have shown that APCC prophylaxis cannot prevent arthropathic progression where pre-existing joint damage exists [32] [33] [34] [35] . No comparable long-term studies have been reported for rFVIIa. Regardless, prophylaxis results in a decreased incidence of bleeding events, an improvement in quality of life and probably can contribute to a decreased rate of progression of joint disease if bleeding patterns are positively impacted.
The importance of early treatment
Early treatment has implications beyond management of acute symptoms, including pain, swelling and decreased mobility; early treatment and bleed control impact development of long-term sequelae, including target joint development and ultimately arthropathy. Clinical data to support the importance of early treatment with FVIIa were first reported in 1993 by Verroust et al. based on results from 220 bleeding events treated with Acset Ò (LFB), a plasma-derived FVIIa concentrate [36] . Lusher confirmed this observation for rFVIIa: the compassionate use program showed an overall efficacy of 63% (mean 5 days to treatment; 13.6 infusions/bleeding event); the dose-finding study reported an efficacy of 72% (mean 9 h to treatment; 3.6 infusions/bleeding event); and the US home-treatment study reported an efficacy of 92% (mean 1.2 h to treatment; 2.3 infusions/bleeding event) [37] . As our scientific understanding of the long-term consequences of poorly controlled bleeding into joints has improved, the concept of early initial treatment, optimally within 1 h, has been emphasized [18] . The advantages of early treatment include: improved efficacy, as confirmed in the prospective WIRK study by Birschmann et al. [38] ; reduced rebleeding events, as reported by Salaj et al. [14] ; and decreased overall cost, as noted by Kavakli et al. [39] . The improved efficacy and reduced rebleeding offered by early treatment directly impact the development and long-term progression of arthropathy.
Approaches to an improved bypassing agent
Understanding how the mechanism of action of rFVIIa affects clinical observation
The goal of a more potent and/or longer-acting rFVIIa variant to reduce dosing and improve patient outcomes dates back almost 20 years [40] . Advances in biotechnology, along with an improved understanding of the mechanism of action of rFVIIa, have guided the development of new variants, each with unique pharmacokinetic properties and different binding affinities for tissue factor (TF), platelets and endothelial protein C receptor (EPCR).
The cell-based model of coagulation [41, 42] addressed many inconsistencies between the traditional coagulation cascade and clinical observation; however, there has long been a debate as to the relative importance of the tissue factor-dependent and platelet-dependent pathways [43] . To address these competing theories, Shibeko et al. described a unified model, with the specific contributions of each pathway dependent on the properties of the rFVIIa variant and its plasma concentration [43, 44] . This model may explain the overall efficacy of specific variants, and possibly guide the development of new products, although as the authors note, it cannot be used to support individual dosing calculations because of patient-specific influences, including unique variations in endogenous thrombin potential.
Beyond this unified model, evidence has emerged of a third mechanism of action, whereby rFVIIa can bind EPCR, displacing its natural ligand, protein C (Fig. 1 ) [45] . At clinical doses of eptacog alfa it is estimated that binding of protein C to EPCR may be reduced 40-65% [45] . This may result in a significant impairment in the generation of the natural anticoagulant, activated protein C, an ensuing reduction in factor Va (FVa) inactivation, and therefore enhanced and sustained thrombin generation [45] . Mouse models with a m(mouse)FVIIa variant designed to bind mEPCR without affecting tissue factor binding (endogenous mFVIIa does not bind mEPCR) [46] show superior hemostatic properties compared with the native protein, further supporting the role of EPCR in hemostasis [47] . The binding of rFVIIa to EPCR has also been suggested to permit the direct activation of FX and to extend the area of co-localization with other membrane-bound coagulation factors on platelet surfaces, in turn enhancing the initial thrombin burst [47] .
EPCR also facilitates rFVIIa endocytosis in vivo, transporting rFVIIa to extravascular tissue, where it may reside for periods of time vastly in excess of its plasma half-life (at least 7 days in one study) [48] . Clark et al. also reported the EPCR-mediated transportation of rFVIIa into joints, and the rFVIIa accumulated in this manner, retained its functional activity [48] . Schut et al. further showed that EPCR-dependent uptake of rFVIIa by megakaryocytes resulted in the production of platelet-like particles containing rFVIIa [49] . The activation of other rFVIIa/EPCRdependent signaling pathways (e.g. PAR1, protease activated receptor 1) has been proposed to have long-term benefits by enhancing the integrity of the vascular endothelium [50] . Such EPCR-mediated observations might explain the success of the once-daily rFVIIa prophylaxis schedule examined by Konkle et al., an outcome that is in contrast to its short plasma half-life, and possibly contribute to the sustained 3-month decrease in the annualized bleeding rate following cessation of prophylaxis, in addition to some decrease in inflammation in recurrently bleeding joints [31, 48] . There are no animal models available to ascertain whether endogenous FVIIa binds EPCR in humans to exert similar effects; however, it might be surmised that the greatly increased levels of endogenous FVIIa at a site of injury could make localized EPCR binding an important component of normal hemostasis. Interestingly, Cramer et al. reported a patient with mild (44%) FVII deficiency who experienced a severe spontaneous intracranial hemorrhage [51] . In this case, the 9729del4-FVII mutation was predicted to disrupt interactions with natural substrates, including EPCR, which could result in a more severe bleeding phenotype than predicted by FVII activity levels alone.
Related to this, two PEGylated rFVIIa variants with very low affinity for EPCR demonstrated a markedly reduced uptake into endothelial cells compared with rFVIIa [52] . Although positioned as a therapeutic advantage as this was expected to result in higher plasma levels, clinical studies with the 40 kDa-PEG rFVIIa variant N7-GP (100 lg kg
À1
) showed peak activity to be 26% that of rFVIIa (90 lg kg À1 ) [53] . In contrast to the rFVIIa prophylaxis study by Konkle et al., once the 3-month N7-GP (200 lg kg
) treatment period ended, there was an immediate and large increase in annualized bleeding rate, suggesting there was no long-term protective effect [54] . Conversely, clinical results from a rFVIIa variant with enhanced EPCR binding (eptacog beta) suggest it may have improved clinical efficacy and reduced dosing requirements compared with eptacog alfa [3, 55] .
These observations suggest that increased rFVIIa affinity for EPCR may be beneficial for the treatment of bleeding events, and a contributor to the longevity of action observed with prophylaxis, and variants that bind EPCR with a higher affinity than eptacog alfa may have enhanced hemostatic properties [45] .
Development of new rFVIIa variants
Three approaches for the development of improved rFVIIa variants have predominated: (i) mutation of the primary amino acid sequence; (ii) use of proprietary technologies (e.g. albumin-fusion) to increase potency or reduce plasma clearance; and (iii) manipulation of the natural glycosylation/post-translational modification (PTM) profile [44, 56] .
Two investigational products with mutated amino acid sequences designed to increase potency (vatreptacog alfa and BAY 86-6150) showed increased activity in preclinical models. However, in clinical studies antibodies to both products were observed, which in some instances crossreacted with rFVIIa (eptacog alfa) and endogenous FVIIa. These observations resulted in the development of both products being halted [40, 57, 58] . A third product with a mutated amino acid sequence, marzeptacog alfa, is currently being examined in a phase 2 study as a subcutaneously administered daily prophylaxis agent [59] . This product was previously studied as an intravenous therapy; however, animal models suggested subcutaneous dosing might offer an increased plasma half-life.
The use of proprietary technologies to extend product half-life, such as PEGylation [54] , XTEN TM (a soluble and biodegradable protein utilized in a similar way to PEG) [60] , CTP-hCG (carboxy-terminal peptide human chorionic gonadotropin-fusion) [61] and albumin-fusion [62] , have also been studied. A PEGylated rFVIIa variant increased human plasma half-life to 15 h; however, a prophylaxis study failed to show a dose-response relationship or a long-term protective effect [54] . No clinical data are available for other extended half-life rFVIIa variants; however, a variant incorporating an XTEN TM unit to increase half-life and an a IIb -integrin-binding antibody fragment to boost platelet affinity demonstrated increased procoagulant activity in vitro [60] . As XTEN TM increases half-life in a manner similar to PEG, and as PEGylatedrFVIIa variants cannot bind EPCR, future clinical results for this variant will be intriguing.
Despite the initial approval of eptacog alfa over 20 years ago, only a single rFVIIa variant has since demonstrated efficacy and safety in a phase 3 clinical study; eptacog beta, which differs by its PTM profile, appears to offer increased efficacy and decreased dosing requirements [3] , possibly because of its increased EPCR binding affinity rather than engineered improvements in plasma half-life. Although changes in the PTM profile of any biologic may be subtle and difficult to rationalize, the ability to improve biological function by manipulation of the PTM profile is an established practice in pharmaceutical research [63, 64] .
Beyond traditional bypassing agents
Parallel to the development of improved rFVIIa variants, several potentially transformative, non-traditional agents are being investigated or have emerged into clinical practice. These products target different proteins in the coagulation cascade (Fig. 1) , and so provide the potential for uniquely personalized therapeutic interventions. Currently, three distinct approaches are used in clinical studies, with one approved for use: bispecific antibodies, antithrombin siRNA and tissue factor pathway inhibitor (TFPI) inhibitors. Other procoagulants such as activated protein C inhibitors, FXa and Super FVa are also being developed, although few data are currently available. A comparison of traditional bypassing agents and newer prophylactic agents is shown in Table 1 Individual doses rarely greater than 300 lg/kg n/a n/a n/a n/a n/a Compared with traditional factor-replacement bypassing agents, emicizumab is currently licensed as a once-weekly subcutaneously administered prophylactic therapy, offering a reduction in frequency or prevention of bleeds and improved patient convenience. In a phase 3 study, inhibitor patients treated with emicizumab experienced a significant decrease in annualized bleeding rate compared with those receiving an on-demand bypassing agent therapy (87% reduction) or a prophylactic bypassing agent regimen (79% reduction), with many subjects (63%) experiencing zero bleeding events on-study [67] . A significant improvement in health-related quality of life was observed for subjects previously utilizing an ondemand bypassing agent regimen; no comparison was reported for subjects formerly using bypassing agent prophylaxis. Serious adverse events can develop during treatment of bleeding events while on emicizumab prophylaxis; during the study with inhibitor patients, 3/103 subjects experienced thrombotic microangiopathy (TMA) and two subjects developed thrombosis [67] . In all cases, the subjects were treating breakthrough bleeds with APCC (> 100 U kg À1 day À1 for > 24 h); these observations were not noted with lower cumulative doses of APCC (or dosing for < 24 h) or with a rFVIIa regimen alone [67] . A single on-study death was reported; this was not attributed to emicizumab or TMA, but rather to uncontrolled rectal bleeding [67] and refusal of transfusion. Five additional deaths have been noted; however, these were all reported as unrelated to emicizumab [68, 69] . It should be noted that TMA has not previously been observed with APCC use alone [70] , and the incidence of thrombosis in inhibitor patients administered rFVIIa or APCC in the absence of other procoagulants is extremely low [17, 71] . These TMA and atypical thromboses differ from prior clinical observations of the use of bypassing agents alone and appear to represent safety events specific to combined emicizumab/APCC therapy. There have been no reports of TMA or thrombosis since risk mitigation strategies limiting the use of APCC and requiring the lowest therapeutic dose of bypassing agent to treat a bleed were implemented. It will remain important to continue to monitor for development of unusual clinical events during widened use, particularly given the long half-life (4 weeks) and the inability to remove emicizumab from systemic circulation prior to emergency care. The manufacturer has created a website to communicate safety information to the US community [72] .
In vitro studies suggest that emicizumab and either APCC or rFVIIa result in greater thrombin generation are also being investigated n/a TFPI, tissue factor pathway inhibitor; APC, activated protein C; APTT, activated partial thromboplastin time; PT, prothrombin time; n/a, data not available.
than a single agent. The effect with APCC at clinically relevant doses is synergistic, resulting in thrombin generation in excess of the normal physiologic range, whereas the effect with rFVIIa is additive and thrombin generation remains below normal [73, 74] . As APCC is a composite product, the cause of this additive effect may be multifactorial; however, data suggest it is primarily a result of the presence of FIX [74] . The lack of thrombotic complications when using emicizumab and rFVIIa may relate to the short plasma half-life of rFVIIa, the inability of emicizumab to bind rFVIIa, and the natural antithrombin-mediated elimination process that prevents excessive rFVIIa-mediated thrombin generation [75] . The treatment of injury and breakthrough bleeding events will require new therapeutic strategies, monitoring of coagulation status, and specific patient education because of the heightened risk of atypical thrombotic events. Based on clinical observation, the lowest dose of rFVIIa or APCC should be used to achieve hemostasis, with preferably a single dose to avoid product accumulation. In the longer term, dose-finding studies with emicizumab and bypassing agents could address some of these safety concerns.
Monitoring patient levels of emicizumab and coagulation status present challenges as no commercial assays are available to measure emicizumab levels and several standard coagulation assays are affected by its presence, including all activated partial thromboplastin time-based assays ( Table 2) . Because of the clinical risk associated with false readings, and as effects may persist for up to 6 months following a patient's last dose, patients should update their emergency medical information and be knowledgeable about the information they must provide to healthcare providers if emergency care is required.
Studies indicate that the incidence of overt clinical bleeds is significantly decreased with emicizumab; however, there are currently no data detailing the development or progression of hemophilic arthropathy, or whether subclinical bleeds are prevented, particularly in patients with target joints. Likewise, because of the risk of thrombotic events, it is not clear whether breakthrough bleeds should be treated as rapidly and aggressively as they would be for patients not administering emicizumab; nor is it known how this decision may impact the long-term development of arthropathy. Experience with FVIII prophylaxis suggests that simply reducing or eliminating overt bleeding may not completely prevent the development or progression of arthropathy [76] [77] [78] . The development of arthropathy while on prophylaxis may challenge what has traditionally been considered an adequate trough level. Long-term use of emicizumab will provide important information about arthropathy development in this population.
Currently, there are no data regarding the use of immune tolerance induction (ITI) while administering emicizumab prophylaxis; questions remain over ITI utility, dose, regimen, etc. The evaluation of ITI progress is complicated as the traditional one-stage NijmegenBethesda assay is inaccurate in the presence of emicizumab (emicizumab is unaffected by heat-treatment protocols); instead, a bovine-based chromogenic assay is recommended.
Emicizumab is the first new prophylaxis agent for inhibitor patients in over 20 years and based upon reported experience it has the ability to transform routine treatment for many hemophilia A patients. Long-term experience will provide important safety data and improved guidance for the treatment of breakthrough bleeds.
Fitusiran
Fitusiran (Sanofi, Paris, France/Alnylam, Cambridge, MA, USA) is an siRNA agent designed to reduce transcription of antithrombin in the liver by targeting antithrombin messenger RNA. As antithrombin inactivates thrombin, FVIIa and FXa in plasma, the net result is to enhance thrombin generation and change the hemostatic balance. Interim results from a phase 2 study (subcutaneous doses of 50 mg or 80 mg once monthly) showed a mean antithrombin reduction of approximately 80% from baseline, with mean peak thrombin levels being restored to the lower end of the normal range in nonhemophilia patients [79] .
A reduction in median annualized bleeding rate in patients with or without inhibitors was noted in interim results, with 48% of subjects recording no bleeding events [79] . However, the death of one subject following repeated FVIII treatment for an exercise-induced hip injury was reported. A review of the subject's computed tomography (CT) scans indicated that the triggering event was a cerebral venous sinus thrombosis, an observation that led to the temporary suspension of the study [80] ; this was lifted in December 2017. Risk mitigation strategies include new clinical guidelines and investigator and patient education recommending reduced doses of replacement factor or bypassing agent to treat breakthrough bleeds [81] . Multiple phase 3 studies in inhibitor and non-inhibitor patients are ongoing with estimated completion dates of mid to late 2019. Although antithrombin is the primary clearance mechanism for rFVIIa, no thrombotic events were reported when rFVIIa was used to treat breakthrough bleeds in inhibitor patients. Unlike emicizumab, which has no antidote, antithrombin levels can be restored with administration of antithrombin concentrate.
Tissue factor pathway inhibitor (TFPI) inhibitors
TFPI is a Kunitz-type serine protease inhibitor that limits both the initiation phase of coagulation by inhibiting the TF-FVIIa complex and the amplification phase by inhibiting FXa (Fig. 1 ) [82] . Currently three TFPI monoclonal antibodies are under investigation in phase 1 or 2 clinical trials (concizumab, BAY 1093884 and PF-06741086) as daily s.c. or i.v. therapies for both inhibitor and non-inhibitor patients. Exvivo spiking studies in hemophilic blood showed that thrombin generation and endogenous thrombin potential can be restored to near normal levels [83] .
A phase 1 study (concizumab) showed no serious adverse events or antidrug antibodies. Currently, dosing is restricted to once-daily administration because of interpatient variability in thrombin generation, elevated Ddimer and prothrombin F 1+2 levels, and non-linear pharmacokinetics [83] [84] [85] . This study showed a tendency towards decreased bleeding, although no statistically significant efficacy data have been reported [85] . TFPI inhibitors are unlikely to be useful to treat an ongoing bleeding event as no hemostatic effect was observed in a hemophilic rabbit bleeding model when dosed after induction of a bleed [86] ; it is currently unknown whether safety issues may exist when hemostatic agents are coadministered during a breakthrough bleeding event.
Activated protein C inhibitors
Activated protein C (APC) is a natural anticoagulant that regulates the propagation phase of coagulation by inactivating FVIIIa and FVa (Fig. 1) . APC is of particular interest as a therapeutic target because persons inheriting hemophilia and the prothrombotic factor V-Leiden mutation (which confers partial APC resistance) have a reduced severity of bleeding [87] . Polderdijk et al. reported that a mutant of the natural APC serpin a 1 -antitrypsin, KRK-a 1 AT, was able to selectively inhibit APC and restore hemostatic balance in hemophilic mouse models [88] . In addition to its procoagulant effect, APC also has anti-inflammatory properties; whether these will be impacted by KRK-a 1 AT is currently unknown. KRKa 1 AT is not yet in clinical development.
Conclusions
For over 20 years, two bypassing agents have been available to treat inhibitor-related bleeding, limiting options for both clinicians and patients; despite this, great advances have been made in the use and understanding of these products. We have now entered a new era in the treatment of inhibitor patients where improved variants of traditional bypassing agents are being developed alongside novel, nonfactor-based, prophylactic agents. Our expanding knowledge of the mechanism of action of rFVIIa has facilitated the design of unique variants with extended half-lives and increased binding to platelets, tissue factor and/or EPCR. Although some studies failed to achieve their clinical endpoints, others have shown promising clinical efficacy, with dosing regimens and outcomes suggesting improvements over the de facto standard, eptacog alfa (NovoSeven Ò ). The addition of improved rFVIIa variants with unique pharmacological and pharmacokinetic profiles will provide new tools to treat bleeding events in inhibitor patients.
Our increased knowledge of the coagulation pathway and the fate of natural procoagulants and anticoagulants, has also presented us with new targets to enhance hemostasis. The first of these, emicizumab, has the potential to transform the treatment of inhibitor patients; however, it also requires clinicians and patients to reconsider how they treat breakthrough bleeds and eliminate the underlying inhibitor itself. Fitusiran and TFPI inhibitors, although still in clinical development, may provide additional prophylactic tools, each targeting a different natural anticoagulant. The possibility of multiple therapeutic targets may allow for a highly personalized approach to prophylaxis therapy, with traditional bypassing agents providing options when breakthrough bleeds occur. Furthermore, the importance of plasma half-life in determining dosing regimen is less relevant for prophylactic agents: rFVIIa has a half-life of a few hours yet can provide a protective effect for months, and fitusiran has a similarly short half-life and is administered once a month.
As we wait for a cure for hemophilia, and information on how a cure may apply to inhibitor patients, these new agents may transform the treatment of inhibitor patients and inhibitor-related bleeds, potentially decreasing morbidity and mortality and improving patients' quality of life [89] . Traditional bypassing agents improved patient convenience and clinical outcomes when they were first introduced; now the combination of bioengineered bypassing agents and novel prophylaxis agents may do the same once again.
